Baseline characteristics
| . | Overall (N = 277) . | Neg/Neg (n = 187) . | Pos/Neg (n = 43) . | Pos/Pos (n = 47) . | P value . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (Min, Max) | 53 (19, 82) | 51 (19, 78) | 51 (27, 72) | 57 (20, 82) | <.01 |
| ≥60 | 57 (21%) | 34 (18%) | 5 (12%) | 18 (38%) | <.01 |
| ELN 2022 risk | |||||
| Favorable | 42 (15%) | 31 (17%) | 8 (19%) | 3 (6%) | <.01 |
| Intermediate | 139 (50%) | 110 (59%) | 17 (40%) | 12 (26%) | |
| Adverse | 96 (35%) | 46 (25%) | 18 (42%) | 32 (68%) | |
| Treatment | |||||
| IC | 224 (81%) | 153 (82%) | 30 (70%) | 41 (87%) | .19 |
| IC+VEN | 53 (19%) | 34 (18%) | 13 (30%) | 6 (13%) | |
| Cytogenetics | |||||
| Diploid | 142 (51%) | 106 (57%) | 22 (51%) | 14 (30%) | <.01 |
| Adverse (non-complex) | 19 (7%) | 7 (4%) | 4 (9%) | 8 (17%) | |
| Complex | 43 (16%) | 22 (12%) | 7 (16%) | 14 (30%) | |
| Others | 73 (26%) | 52 (28%) | 10 (23%) | 11 (23%) | |
| Mutations | |||||
| ≥1 adverse∗ | 64 (23%) | 29 (16%) | 12 (28%) | 23 (49%) | <.01 |
| ASXL1 | 17 (6%) | 6 (3%) | 3 (7%) | 8 (17%) | .02 |
| CEBPAbi/BZIP | 9 (3%) | 7 (4%) | 1 (2%) | 1 (2%) | .01 |
| FLT3ITD | 68 (25%) | 52 (28%) | 8 (19%) | 8 (17%) | <.01 |
| IDH1 | 17 (6%) | 10 (5%) | 4 (9%) | 3 (6%) | .80 |
| IDH2 | 38 (14%) | 31 (17%) | 5 (12%) | 2 (4%) | .13 |
| NPM1 | 83 (30%) | 68 (36%) | 9 (21%) | 6 (13%) | <.01 |
| NRAS | 30 (11%) | 20 (11%) | 8 (19%) | 2 (4%) | .18 |
| PTPN11 | 20 (7%) | 10 (5%) | 6 (14%) | 4 (9%) | .18 |
| RUNX1 | 19 (7%) | 11 (6%) | 2 (5%) | 6 (13%) | .60 |
| TP53 | 21 (8%) | 7 (4%) | 3 (7%) | 11 (23%) | <.01 |
| . | Overall (N = 277) . | Neg/Neg (n = 187) . | Pos/Neg (n = 43) . | Pos/Pos (n = 47) . | P value . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (Min, Max) | 53 (19, 82) | 51 (19, 78) | 51 (27, 72) | 57 (20, 82) | <.01 |
| ≥60 | 57 (21%) | 34 (18%) | 5 (12%) | 18 (38%) | <.01 |
| ELN 2022 risk | |||||
| Favorable | 42 (15%) | 31 (17%) | 8 (19%) | 3 (6%) | <.01 |
| Intermediate | 139 (50%) | 110 (59%) | 17 (40%) | 12 (26%) | |
| Adverse | 96 (35%) | 46 (25%) | 18 (42%) | 32 (68%) | |
| Treatment | |||||
| IC | 224 (81%) | 153 (82%) | 30 (70%) | 41 (87%) | .19 |
| IC+VEN | 53 (19%) | 34 (18%) | 13 (30%) | 6 (13%) | |
| Cytogenetics | |||||
| Diploid | 142 (51%) | 106 (57%) | 22 (51%) | 14 (30%) | <.01 |
| Adverse (non-complex) | 19 (7%) | 7 (4%) | 4 (9%) | 8 (17%) | |
| Complex | 43 (16%) | 22 (12%) | 7 (16%) | 14 (30%) | |
| Others | 73 (26%) | 52 (28%) | 10 (23%) | 11 (23%) | |
| Mutations | |||||
| ≥1 adverse∗ | 64 (23%) | 29 (16%) | 12 (28%) | 23 (49%) | <.01 |
| ASXL1 | 17 (6%) | 6 (3%) | 3 (7%) | 8 (17%) | .02 |
| CEBPAbi/BZIP | 9 (3%) | 7 (4%) | 1 (2%) | 1 (2%) | .01 |
| FLT3ITD | 68 (25%) | 52 (28%) | 8 (19%) | 8 (17%) | <.01 |
| IDH1 | 17 (6%) | 10 (5%) | 4 (9%) | 3 (6%) | .80 |
| IDH2 | 38 (14%) | 31 (17%) | 5 (12%) | 2 (4%) | .13 |
| NPM1 | 83 (30%) | 68 (36%) | 9 (21%) | 6 (13%) | <.01 |
| NRAS | 30 (11%) | 20 (11%) | 8 (19%) | 2 (4%) | .18 |
| PTPN11 | 20 (7%) | 10 (5%) | 6 (14%) | 4 (9%) | .18 |
| RUNX1 | 19 (7%) | 11 (6%) | 2 (5%) | 6 (13%) | .60 |
| TP53 | 21 (8%) | 7 (4%) | 3 (7%) | 11 (23%) | <.01 |
Max, maximum; Min, minimum.
One or more adverse mutation as defined by the ELN2022 criteria.1